Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Theralase Technologies ( (TSE:TLT) ) just unveiled an announcement.
Theralase Technologies reported new preclinical data showing that its light-activated Ruvidar molecule, when combined with recombinant human interferon alpha-2b, significantly increased bladder cancer cell death in vitro. In T24 human bladder cancer cells, the combination produced 50% to 65% higher total cell kill than interferon alone, with dose-dependent cytotoxicity observed for both agents.
Researchers said Ruvidar directly kills tumor cells and primes the immune system, while interferon slows tumor growth and promotes immune-mediated clearance, creating a strong additive effect. The findings underpin Theralase’s planned combination clinical study in patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, potentially strengthening the company’s position in an area of high unmet medical need.
The most recent analyst rating on (TSE:TLT) stock is a Hold with a C$0.25 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.
Spark’s Take on TSE:TLT Stock
According to Spark, TipRanks’ AI Analyst, TSE:TLT is a Neutral.
The score is held down primarily by weak financial performance—very large losses versus a small and declining revenue base, ongoing cash burn, and substantial equity erosion. Technicals provide some support with strong recent momentum (price above major moving averages and positive MACD), but elevated RSI suggests the move may be stretched. Valuation remains unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on TSE:TLT stock, click here.
More about Theralase Technologies
Theralase Technologies is a Toronto-based clinical-stage pharmaceutical company developing energy-activated small molecules, including its Ruvidar platform, to destroy cancer, bacteria and viruses. The company focuses on bladder cancer, particularly high-risk, Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, aiming to improve efficacy and durability of response versus existing therapies.
Average Trading Volume: 187,308
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$73.26M
For detailed information about TLT stock, go to TipRanks’ Stock Analysis page.